Document is current
Any future updates will be listed below
-
Authors
Whitman, Jacob
Kozaily, Elie
Michos, Erin D.
Silverman, Daniel N.
Fudim, Marat
Mentz, Robert J.
Tedford, Ryan J.
Rao, Vishal N.
-
Funding
Funding for this research was provided by:
Medical University of South Carolina
- License Information
-
More Information
Article History
Accepted: 5 March 2025
First Online: 19 March 2025
Declarations
:
: Dr. Michos reports consulting for Amgen, Arrowhead, AstraZeneca, Bayer, Boehringer Ingelheim, Edwards Lifescience, Eli Lilly, Esperion, Iois, Medtronic, Merck, New Amsterdam, Novartis, and Novo Nordisk. Dr. Marat Fudim was supported by the NIH, Alleviant, Gradient, Reprieve, Sardocor, and Doris Duke. He is a consultant/has ownership interest in Abbott, Acorai, Ajax, Alio Health, Alleviant, Artha, Audicor, AxonTherapies, Bodyguide, Bodyport, Boston Scientific, Broadview, Cadence, Cardiosense, Cardioflow, CVRx, Daxor, Edwards LifeSciences, Echosens, EKO, Endotronix, Feldschuh Foundation, Fire1, FutureCardia, Galvani, Gradient, Hatteras, HemodynamiQ, Impulse Dynamics, Medtronic, Merck, NovoNordisk, NucleusRx, NXT Biomedical, Omega, Orchestra, Parasym, Pharmacosmos, Presidio, Procyreon, Proton Intelligence, Puzzle, ReCor, SCPharma, Shifamed, Splendo, STAT Health, Summacor, SyMap, Terumo, Vascular Dynamics, Vironix, Viscardia, Zoll. Dr. Robert J. Mentz received research support and honoraria from Abbott, Alleviant Medical, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead, Innolife, Eli Lilly, Lexicon, Medtronic, Medable, Merck, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Relypsa, Reprieve Cardiovascular, Respicardia, Roche, Rocket Pharmaceuticals, Sanofi, Verily, Vifor, Windtree Therapeutics, and Zoll. Dr. Tedford reports no disclosures relative to this manuscript. Dr. Tedford is Editor for the Journal of Heart and Lung Transplantation. He reports general disclosures to include consulting relationships with and receiving honorarium from Abbott, Acorai, Adona, Aria CV Inc., Acceleron/Merck, Alleviant, Boston Scientific, Cytokinetics, Edwards LifeSciences, Gradient, Medtronic, Morphic Therapeutics, Restore Medical, and United Therapeutics. Dr. Tedford serves on steering committee for Abbott, Edwards, Endotronix, and Merck as well as a research advisory board for Abiomed. He also does hemodynamic core lab work for Merck. All other authors report no relevant conflicts of interest.
: This review article does not contain any studies with human or animal subjects performed by any of the authors.
